Dynamic whole-body [¹⁸F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer.

"Declarations Ethics approval and consent to participateThis study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Danish Medicines Agency (2019083844) and Central Denmark Region Committees on Health Research Ethics (1-10-72-195-19). Written informed consent was obtained from all individual participants included in the study. Consent for publicationNot applicable. Availability of data and materialsThe data that support the findings of this study is available from the corresponding author upon reasonable request. Competing InterestsThe authors have no relevant financial or non-financial interests to disclose. Competing Interests The authors have no relevant financial or non-financial interests to disclose."

"Funding MAP received financial support from Aarhus Universitets Forskningsfond (AUFF-E-2017-7-17), Faculty of Health, Aarhus University, Aarhus, Denmark and the Steno Diabetes Centre Aarhus (SDCA), Denmark, which is partially funded by an unrestricted donation from the Novo Nordisk Foundation."

"Trial registration ClinicalTrials.gov: NCT04150731, https://clinicaltrials.gov/study/NCT04150731"